Highlights Inventiva

Equities

IVA

FR0013233012

Market Closed - Euronext Paris Other stock markets 11:35:20 2024-04-29 am EDT			After market 02:13:26 pm
2.97 ^EUR	-1.00%		2.973	+0.10%

Apr. 22	Inventiva: UBS Group falls below 5% threshold	CF
Apr. 18	Transcript : Inventiva S.A. - Special Call

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Inventiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
ADRs End Flat, Ehang Holdings Ltd. Climbs 15.6%	Mar. 19	DJ
Inventiva: positive results from phase 2 clinical trial	Mar. 19	CF
Inventiva S.A. Announces Positive Results from the Phase II, Legend, Proof-Of-Concept Study Combining Lanifibranor with Empagliflozin	Mar. 18	CI
Inventiva: NATiV3 study pause lifted	Mar. 08	CF
Inventiva Announces Voluntary Pause on Screening and Randomization of Its NATiV3 clinical trial	Mar. 07	CI
Inventiva: share price falls, phase III recruitment suspended	Feb. 16	CF
Inventiva S.A. Provides Update on its Clinical Trial NATiV3	Feb. 15	CI
Inventiva: second tranche drawn from the EIB	Jan. 11	CF
Inventiva Says First Person Randomized in China in Phase 3 Trial of Lanifibranor for Nonalcoholic Steatohepatitis	Dec. 20	MT
Inventiva Announces the Randomization of the First Patient in China in the NATiV3 Clinical Trial and Provides an Update on Its Clinical Development Program	Dec. 20	CI
Inventiva S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-28	CI
Inventiva Gains 17% on Licensing Deal for Fatty Liver Disease Drug Candidate in Japan, South Korea	23-09-21	MT
Inventiva S.A. and Hepys Pharma, Inc. Announce Exclusive Licensing Agreement to Develop and Commercialize Lanifibranor in Japan and South Korea	23-09-20	CI
Inventiva, Hepalys Pharma Sign Exclusive Licensing Deal to Develop, Sell Lanifibranor in Japan, South Korea	23-09-20	MT
Inventiva Announces Positive Topline Results from the Investigator-Initiated Phase Ii Clinical Trial Evaluating Lanifibranor in Patients with T2d and NAFLD	23-06-13	CI
Inventiva Says Partner Sino Biopharm Gets Regulatory Nod to Launch Lanifibranor Trial in China	23-05-25	MT
Inventiva S.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-29	CI
Inventiva S.A. Announces Changes to the Clinical Development of Lanifibranor, Including Plans for New Phase III Trial in Patients with NASH and Compensated Cirrhosis	23-01-04	CI
Inventiva Provides Update on Development of cedirogant by AbbVie	22-10-31	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Inventiva

Equities

IVA

FR0013233012

Highlights

Filters